Factors associated with change in exacerbation frequency in COPD

Gavin C Donaldson, Hanna Müllerova, Nicholas Locantore, John R Hurst, Peter M A Calverley, Jorgen Vestbo, Antonio Anzueto, Jadwiga A Wedzicha, Gavin C Donaldson, Hanna Müllerova, Nicholas Locantore, John R Hurst, Peter M A Calverley, Jorgen Vestbo, Antonio Anzueto, Jadwiga A Wedzicha

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) can be categorized as having frequent (FE) or infrequent (IE) exacerbations depending on whether they respectively experience two or more, or one or zero exacerbations per year. Although most patients do not change category from year to year, some will, and the factors associated with this behaviour have not been examined.

Methods: 1832 patients completing two year follow-up in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) study were examined at baseline and then yearly. Exacerbations were defined by health care utilisation. Patient characteristics compared between those patients who did or did not change exacerbation category from year 1 to year 2.

Findings: Between years 1 and 2, 221 patients (17%) changed from IE to FE and 210 patients (39%) from FE to IE. More severe disease was associated with changing from IE to FE and less severe disease from FE to IE. Over the preceding year, small falls in FEV1 and 6-minute walking distance were associated with changing from IE to FE, and small falls in platelet count associated with changing from FE to IE.

Conclusion: No parameter clearly predicts an imminent change in exacerbation frequency category.

Trial registration: SCO104960, clinicaltrials.gov identifier NCT00292552.

Figures

Figure 1
Figure 1
Timing of assessment and patient exacerbation categorization during the initial two years of the ECLIPSE study.
Figure 2
Figure 2
Distribution of exacerbation frequency change. All COPD patients (A) and in patients classified as IE (B) and FE (C) in year 1.

References

    1. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370:786–796. doi: 10.1016/S0140-6736(07)61382-8.
    1. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003;48:1204–1213.
    1. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–1422. doi: 10.1164/ajrccm.157.5.9709032.
    1. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–120. doi: 10.1136/thorax.55.2.114.
    1. Donaldson G, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–852. doi: 10.1136/thorax.57.10.847.
    1. Soler-Cataluna JJ, Martinez-Garcia MA. Roman Sanchez P, Salcedo E, Navarro M, Ochando R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925–931. doi: 10.1136/thx.2005.040527.
    1. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W. et al.Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138. doi: 10.1056/NEJMoa0909883.
    1. McGuire A, Irwin DE, Fenn P, Gray A, Anderson P, Lovering A, MacGowan A. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2001;4:370–375. doi: 10.1046/j.1524-4733.2001.45049.x.
    1. Borg S, Ericsson A, Wedzicha J, Gulsvik A, Lundback B, Donaldson GC, Sullivan SD. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health. 2004;7:153–167. doi: 10.1111/j.1524-4733.2004.72318.x.
    1. Quint JK, Donaldson GC, Hurst JR, Goldring JJ, Seemungal TR, Wedzicha JA. Predictive accuracy of patient-reported exacerbation frequency in COPD. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2011;37:501–507. doi: 10.1183/09031936.00035909.
    1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M. et al.Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med. 2013;187:347–365. doi: 10.1164/rccm.201204-0596PP.
    1. Donaldson GC, Mullerova H, Locantore NW, Hurst JR, Vestbo J, Anzueto A, Wedzicha JA. Factors Associated With Change In COPD Exacerbation Frequency Phenotype. J Respir Crit Care Med. 2011;183:A5362.
    1. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W. et al.Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2008;31:869–873. doi: 10.1183/09031936.00111707.
    1. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40.
    1. Spruit MA, Watkins ML, Edwards LD, Vestbo J, Calverley PM, Pinto-Plata V, Celli BR, Tal-Singer R, Wouters EF. Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med. 2010;104:849–857. doi: 10.1016/j.rmed.2009.12.007.
    1. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;158:1384–1387. doi: 10.1164/ajrccm.158.5.9710086.
    1. Celli BR, Cote CG, Marin JM, Casanova C, Montes De Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–1012. doi: 10.1056/NEJMoa021322.
    1. Gietema HA, Muller NL, Fauerbach PV, Sharma S, Edwards LD, Camp PG, Coxson HO. Quantifying the extent of emphysema: factors associated with radiologists’ estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol. 2011;18:661–671. doi: 10.1016/j.acra.2011.01.011.
    1. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res. 2011;12:146. doi: 10.1186/1465-9921-12-146.
    1. Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J. 2003;22:931–936. doi: 10.1183/09031936.03.00038303.
    1. Aaron SD, Ramsay T, Vandemheen K, Whitmore GA. A threshold regression model for recurrent exacerbations in chronic obstructive pulmonary disease. J Clin Epidemiol. 2010;63:1324–1331. doi: 10.1016/j.jclinepi.2010.05.007.
    1. Wilkinson TMA, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006;129:317–324. doi: 10.1378/chest.129.2.317.
    1. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:1618–1623. doi: 10.1164/ajrccm.164.9.2105011.
    1. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Molken MR. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:435–444.
    1. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax. 2006;61:472–477. doi: 10.1136/thx.2005.052449.
    1. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2004;23:28–33. doi: 10.1183/09031936.03.00034603.
    1. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613. doi: 10.1164/ajrccm.161.5.9908022.
    1. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298–1303. doi: 10.1164/rccm.200310-1443OC.
    1. Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Wang C, Bourbeau J. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2010;35:1022–1030. doi: 10.1183/09031936.00079409.
    1. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK. et al.Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
    1. Biljak VR, Pancirov D, Cepelak I, Popovic-Grle S, Stjepanovic G, Grubisic TZ. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011;22:466–470. doi: 10.3109/09537104.2011.573887.
    1. Vlacha V, Feketea G. Thrombocytosis in pediatric patients is associated with severe lower respiratory tract inflammation. Arch Med Res. 2006;37:755–759. doi: 10.1016/j.arcmed.2006.02.009.
    1. Pitchford SC. Novel uses for anti-platelet agents as anti-inflammatory drugs. Br J Pharmacol. 2007;152:987–1002.
    1. Ferroni P, Vazzana N, Riondino S, Cuccurullo C, Guadagni F, Davi G. Platelet Function in Health and Disease: from Molecular Mechanisms, Redox Considerations to Novel Therapeutic Opportunities. Antioxid Redox Signal. 2012;17:1447–1485. doi: 10.1089/ars.2011.4324.
    1. Tsai NW, Lin TK, Chang WN, Jan CR, Huang CR, Chen SD, Cheng KY, Chiang YF, Wang HC, Yang TM. et al.Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke. Crit Care. 2011;15:R163. doi: 10.1186/cc10303.
    1. Huang CC, Chan WL, Chen YC, Chen TJ, Chou KT, Lin SJ, Chen JW, Leu HB. Statin Use and Hospitalization in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study in Taiwan. Clin Ther. 2011;33:1365–1370. doi: 10.1016/j.clinthera.2011.08.010.
    1. Hernandes NA, Wouters EF, Meijer K, Annegarn J, Pitta F, Spruit MA. Reproducibility of 6-minute walking test in patients with COPD. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2011;38:261–267. doi: 10.1183/09031936.00142010.
    1. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C. et al.Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365:1184–1192. doi: 10.1056/NEJMoa1105482.
    1. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554. doi: 10.1056/NEJMoa0805800.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren